FIP 2024
FIP 2024 will take place in-person at Hart House (7 Hart House Cir., Toronto, ON M5S 3H3).
Welcome Address, Oral Sessions, Keynote Speech:
These sessions will take place in the Great Hall of Hart House.
Poster Sessions:
This year, poster presentations and the poster Q/A sessions will be held in-person in the East Common Room of Hart House.
Reception:
Join us at the end of the day for the award ceremony, closing remarks, platform updates, and an after-party, all taking place in the Great Hall of Hart House!
Welcome Address, Oral Sessions, Keynote Speech:
These sessions will take place in the Great Hall of Hart House.
Poster Sessions:
This year, poster presentations and the poster Q/A sessions will be held in-person in the East Common Room of Hart House.
Reception:
Join us at the end of the day for the award ceremony, closing remarks, platform updates, and an after-party, all taking place in the Great Hall of Hart House!
KEYNOTE
Dr. Carmella Evans-MolinaDr. Carmella Evans-Molina is the Eli Lilly Professor of Pediatric Diabetes at the Indiana University School of Medicine in Indianapolis, IN, where she serves as Director of the IU Center for Diabetes and Metabolic Diseases and Program Leader for the Diabetes Research Group in the Herman B Wells Center for Pediatric Research. She is a Staff Physician at the Roudebush Veteran's Affairs (VA) Medical Center.
Her research is focused on understanding the molecular and signaling pathways operating within pancreatic β cells that drive the transition from a compensated state of euglycemia to a decompensated state of hyperglycemia in both type 1 (T1D) and type 2 diabetes (T2D). In basic science work, Dr. Evans-Molina studies how impaired calcium signaling within the β cell secretory pathway leads to impairments in insulin secretion, processing, and trafficking and activation of organelle-specific stress pathways such as endoplasmic reticulum and Golgi stress. Dr. Evans-Molina's translational and clinical projects harness knowledge gained from studying stress within the β cell to develop biomarker strategies with the goal of informing T1D screening strategies and identifying targets for disease-modifying therapies. |
|
Her research is funded by the NIH, the VA Research Program, the JDRF, and the Helmsley Charitable Trust. She is an investigator in the NIH-funded Type 1 Diabetes Trialnet, RADIANT, and TIDAPC/DREAM Networks. Dr. Evans-Molina is a Co-Executive Director of the Network for Pancreatic Organ Donors with Diabetes (nPOD), Co-PI of the NIH-funded Integrated Islet Distribution Program, and President of the Immunology of Diabetes Society (IDS).
The title for Dr. Carmella Evans-Molina's talk will be “New Paradigms for the Treatment of Type 1 Diabetes” .
____________________________________________________________________
The year 2021 marked the centennial anniversary of Banting and Best's landmark discovery of insulin. This discovery and the rapid clinical deployment of insulin as a therapy transformed type 1 diabetes (T1D) from a once fatal diagnosis into a medically manageable chronic condition. In the intervening 100 years, remarkable advances have been made in our understanding of the natural history, pathophysiology, and treatment of T1D. In parallel, an improved understanding of the insulin molecule has informed the development of optimized insulin analogues for therapeutic use in combination with continuous glucose monitoring systems and automated insulin delivery. Key discoveries related to these advances will be highlighted in the talk. However, despite these revolutionary advances in insulin delivery, less than a quarter of individuals living with T1D are able to achieve optimal blood glucose control. Chronic hyperglycemia leads to a number of diabetes-associated complications, including retinopathy, cardiovascular disease, neuropathy, nephropathy, and reduced life expectancy, underscoring the need to develop novel strategies aimed at T1D prevention. This presentation will describe the current status of disease-modifying therapies in T1D, including the recent approval of teplizumab as the first treatment to slow disease progression in at-risk individuals. Key knowledge gaps will be highlighted including the role of the pancreatic beta cell in disease progression and emerging therapies with the potential to both improve beta cell health and modulate immune function. Finally, strategies to identify and validate biomarkers of early beta cell stress for prediction of T1D risk will be discussed.
__________________________________________________________________________
The title for Dr. Carmella Evans-Molina's talk will be “New Paradigms for the Treatment of Type 1 Diabetes” .
____________________________________________________________________
The year 2021 marked the centennial anniversary of Banting and Best's landmark discovery of insulin. This discovery and the rapid clinical deployment of insulin as a therapy transformed type 1 diabetes (T1D) from a once fatal diagnosis into a medically manageable chronic condition. In the intervening 100 years, remarkable advances have been made in our understanding of the natural history, pathophysiology, and treatment of T1D. In parallel, an improved understanding of the insulin molecule has informed the development of optimized insulin analogues for therapeutic use in combination with continuous glucose monitoring systems and automated insulin delivery. Key discoveries related to these advances will be highlighted in the talk. However, despite these revolutionary advances in insulin delivery, less than a quarter of individuals living with T1D are able to achieve optimal blood glucose control. Chronic hyperglycemia leads to a number of diabetes-associated complications, including retinopathy, cardiovascular disease, neuropathy, nephropathy, and reduced life expectancy, underscoring the need to develop novel strategies aimed at T1D prevention. This presentation will describe the current status of disease-modifying therapies in T1D, including the recent approval of teplizumab as the first treatment to slow disease progression in at-risk individuals. Key knowledge gaps will be highlighted including the role of the pancreatic beta cell in disease progression and emerging therapies with the potential to both improve beta cell health and modulate immune function. Finally, strategies to identify and validate biomarkers of early beta cell stress for prediction of T1D risk will be discussed.
__________________________________________________________________________